Biocytogen Strengthens Global IP Strategy with Japan Patent for RenMab™ Platform

The biotech leader’s RenMice® family earns key patent in Japan, reinforcing its global antibody innovation footprint.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) has secured a significant milestone with the Japan Patent Office granting a key invention patent for its RenMab™ fully human antibody mouse platform. This recognition strengthens the company’s global intellectual property strategy and affirms the innovation behind its RenMice® family of platforms.

RenMab™ mice, developed using Biocytogen’s proprietary SUPCE® gene-editing technology, feature fully human immunoglobulin genes, enabling them to generate high-diversity, native-like antibodies without requiring humanization. As the company explained, “This advancement streamlines antibody drug development and lowers immunogenicity risk.”

RenMice platforms (RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™) have been widely adopted by over 20 global biopharma firms, including Merck KGaA and Johnson & Johnson. These platforms have produced over 1 million antibody sequences and helped generate hundreds of promising therapeutic candidates across 1,000+ targets. As of end-2024, Biocytogen had signed nearly 200 global licensing and development agreements.

“Our patent coverage now spans nearly 10 countries, including the U.S., China, and Japan,” the company said. “With 40 additional applications under review, we’re committed to expanding protections worldwide.”

Headquartered in Beijing with global offices in the U.S. and Germany, Biocytogen continues to advance next-gen antibody therapies through its RenBiologics™ and BioMice™ sub-brands, offering powerful tools for drug discovery and preclinical research.